Apatinib is a specific VEGFR‐2 receptor antagonist that competitively binds to the VEGFR‐2 receptor, blocks VEGF‐mediated signaling, inhibits tumor angiogenesis, and thereby controls tumor growth.33 At present, there are more than 30 clinical studies on the treatment of advanced lung cancer with apatinib. Here, VEGFA is linked to lung carcinoma.